• PIH13 -COST-EFFECTIVENESS OF REDUCING MULTIPLE BIRTHS- IN-VITRO FERTILIZATION STRATEGIES IN CANADA

    Oct 1, 2009, 00:00

  • PMH73 POTENTIAL ABUSE OF COMBINATION ANALGESICS- A DATABASE ANALYSIS

    Oct 1, 2009, 00:00

  • PCN132 UTILITY LIBRARY TO CAPTURE UTILITIES IN THE AREA OF ONCOLOGY

    Oct 1, 2009, 00:00

  • PCV47 THE QUANTIFICATION OF THE RELATIONSHIP BETWEEN HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND ALL-CAUSE MORTALITY

    Oct 1, 2009, 00:00

  • PCN93 HEALTH ECONOMICS OF HPV VACCINATION IN AUSTRIA-COST-EFFECTIVENESS OF VACCINATING 12 YEAR OLD GIRLS

    Oct 1, 2009, 00:00

  • PHP3 EFFECTS OF THE IMPLEMENTATION OF AN ANNUAL CO-PAYMENT LIMIT FOR PRESCRIPTION DRUGS IN AUSTRIA

    Oct 1, 2009, 00:00

  • WP1 COMPARISON OF A DIRECT AND AN INDIRECT METHOD TO DERIVE WILLINGNESS TO PAY FOR COMPLEX HEALTH STATES IN OBSTETRICS

    Oct 1, 2009, 00:00

  • PCV10 ECONOMIC VALUE OF RESTING HEART RATE AS AN INDEPENDENT CARDIOVASCULAR RISK FACTOR IN STABLE ANGINA PATIENTS

    Oct 1, 2009, 00:00

  • PCN80 THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN- RESULTS FROM A COST-EFFECTIVEN ...

    Oct 1, 2009, 00:00

  • PMS11 LONG-TERM MORTALITY RATES AFTER INCIDENT FRACTURES IN A POPULATION-BASED COHORT OF MEN AND WOMEN

    Oct 1, 2009, 00:00

  • PCV7 ASSOCIATION BETWEEN DEYO-CHARLSON COMORBIDITY INDEX SCORE AND SUBSEQUENT CARDIOVASCULAR DISEASE EVENTS AND ASSOCIATED COST IN DYSLIPIDEMIA MANAGEMENT AMONG MANAGED CARE PATIENTS IN THE UNITED STATES

    Oct 1, 2009, 00:00

  • PCV26 PRACTICE PATTERNS AND QUALITY OF LIFE IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE NORDIC COUNTRIES- RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II)

    Oct 1, 2009, 00:00

  • PCV128 LOADING WITH WARFARIN PROLONGS LENGTH OF HOSPITAL STAY IN PATIENTS WITH ATRIAL FIBRILLATION

    Oct 1, 2009, 00:00

  • PCN33 QUALITY OF LIFE OF PATIENTS WITH NON-HODGKIN LYMPHOMA AT THE SOCIAL SECURITY MEXICAN INSTITUTE

    Oct 1, 2009, 00:00

  • MO4 BAYESIAN GENERALIZED LINEAR MODELLING OF THE RELATIONSHIP BETWEEN HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX AND HEALTH UTILITIES INDEX MARK III IN EARLY AND LATE RHEUMATOID ARTHRITIS- DATA FROM THE PREMIER AND ARMADA TRIALS

    Oct 1, 2009, 00:00

  • PCN124 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) ON CHRONIC (CP), ACCELERATED (AP) AND BLAST (BP) PHASES IN BRAZIL

    Oct 1, 2009, 00:00

  • PSY10 TREATING FIBROMYALGIA WITH DULOXETINE- WHAT IS THE ASSOCIATION BETWEEN AVERAGE DAILY DOSE, MEDICATION ADHERENCE, AND HEALTH CARE COSTS?

    Oct 1, 2009, 00:00

  • PMS37 DOES GENERIC ALENDRONATE REALLY SAVE MONEY IN THE TREATMENT OF OSTEOPOROSIS GIVEN SUB-OPTIMAL REAL LIFE COMPLIANCE? AN EXAMPLE FROM THE DANISH SETTING

    Oct 1, 2009, 00:00

  • CASE2 EXPERIDE SUPLEMENTAR

    Oct 1, 2009, 00:00

  • PMS88 MANAGEMENT AND COST OF LOW BACK PAIN IN-HOSPITAL- HOW A LONGITUDINAL HOSPITAL DATA BASE DESCRIBES THE REAL PRACTICES?

    Oct 1, 2009, 00:00

  • PRS1 A COMPARISON OF EFFICACY AND SAFETY OF FLUTICASONE WITH BUDESONIDE AND BECLOMETHASONE IN 1-2 DOSE RATIO IN THE TREATEMENT OF BRONCHIAL ASTHMA

    Oct 1, 2009, 00:00

  • PMS80 ASSOCIATION BETWEEN ANXIETY AND HRQOL IN PATIENTS WITH LOWER LIMB OSTEOARTHRITIS

    Oct 1, 2009, 00:00

  • PIN73 CRITICAL CARE ADMISSIONS FOR PNEUMONIA IN ENGLAND

    Oct 1, 2009, 00:00

  • PMS12 PROBABILISTIC ANALYSIS OF BUDGETARY IMPACT- GLUCOSAMINE IN KNEE OSTEOARTHRITIS TREATMENT

    Oct 1, 2009, 00:00

  • PCN170 PUBLIC REGULATION OF THE CANCER DRUGS MARKET IN FRENCH HOSPITALS

    Oct 1, 2009, 00:00

  • PHP83 EVALUATING PHARMACEUTICAL MARKETING TOOLS IMPLEMENTED BY THE COMPANIES, OBSERVED AND EXPERIENCED BY PHYSICIANS IN PAKISTAN

    Oct 1, 2009, 00:00

  • VA5 INDIVIDUALLY-BASED DYNAMIC MODELING OF INFECTIOUS DISEASES- COST-EFFECTIVENESS OF ADOLESCENT PERTUSSIS BOOSTER VACCINATION FOR THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PMC72 DEVELOPMENT OF THE ACCEPT QUESTIONNAIRE TO ASSESS ACCEPTABILITY OF LONG TERM TREATMENTS- QUALITATIVE STEPS

    Oct 1, 2009, 00:00

  • PMC39 USING MIXED TREATMENT COMPARISON MODELING TO COMPARE PROPORTIONS OF NAIVE HBEAG(+) CHB PATIENTS WHO ACHIEVED UNDETECTABLE HBV DNA

    Oct 1, 2009, 00:00

  • PMS71 PREDICTING CHANGES IN EQ-5D UTILITY SCORE VIA PASl OR HAQ IN PSORIATIC ARTHRITIS PATIENTS

    Oct 1, 2009, 00:00

  • PCN35 BUDGETARY IMPACT OF ORAL CHEMOTHERAPY- REAL-WORLD DATA ANALYSIS FROM PAYERS PERSPECTIVES IN BRAZIL

    Oct 1, 2009, 00:00

  • PMH40 COST-EFFECTIVENESS ANALYSIS OF THE INCREDIBLE YEARS PARENT PROGRAM AS A PREVENTIVE INTERVENTION

    Oct 1, 2009, 00:00

  • PHP77 NEW DRUGS EVALUATION IN SPAIN- THE JOINT COMMITTEE OF NEW DRUGS EVALUATION EXPERIENCE

    Oct 1, 2009, 00:00

  • PMH43 THE COST-EFFECTIVENESS OF QUETIAPINE XR IN THE PREVENTION OF RELAPSE AND HOSPITALIZATION IN SCHIZOPHRENIA

    Oct 1, 2009, 00:00

  • PSS3 TREATMENT PERSISTENCY OF XALATAN-XALACOM, LUMIGANGANFORT AND TRAVATAN-DUOTRAV- AN ANALYSIS CONDUCTED ON THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE

    Oct 1, 2009, 00:00

  • PMS95 REAL WORLD DATABASE ANALYSIS- USAGE AND ECONOMIC IMPACT OF ANTI-TNFS AS SECOND LINE THERAPY FOR RHEUMATOID ARTHRITIS PATIENTS IN THE PUBLIC HEALTH CARE SECTOR IN BRAZIL

    Oct 1, 2009, 00:00

  • PCV132 DIFFERENCES IN PERSISTENCE BETWEEN CCBS WHEN COMBINED WITH AN A2RA OR AN ACE ANTIHYPERTENSIVE IN AUSTRALIA

    Oct 1, 2009, 00:00

  • PIN11 COST EFFECTIVENESS ANALYSIS OF ELDERLY POLYSACCHARIDE PNEUMOCOCCAL VACCINATION IN SAO PAULO STATE

    Oct 1, 2009, 00:00

  • EE4 MARKET ACCESS IN GERMANY- WHERE NEXT?

    Oct 1, 2009, 00:00

  • PRS29 QUALITY OF LIFE AND WORK PRODUCTIVITY IN ALLERGIC RHINITIS PATIENTS SUFFERING FROM BOTH NASAL AND OCULAR SYMPTOMS-AN OBSERVATIONAL, CROSS SECTIONAL STUDY IN 4 COUNTRIES IN EUROPE

    Oct 1, 2009, 00:00

  • PND21 COST-EFFECTIVENESS OF RASAGILINE COMPARED TO OTHER FIRST LINE TREATMENT OPTIONS OF EARLY PARKINSONS DISEASE IN THE UNITED STATES

    Oct 1, 2009, 00:00

  • PMC40 ESTIMATING THE NET HERD EFFECT INDUCED BY PCV-VACCINES- A HYPOTHESIS GENERATING STUDY

    Oct 1, 2009, 00:00

  • PMS87 IMPACT OF RHEUMATOID ARTHRITIS (RA) ON WORKING CONDITIONS AND INCOME

    Oct 1, 2009, 00:00

  • PIN72 TRANSLATION OF THE HIV PATIENT SYMPTOMS PROFILE INTO 5 LANGUAGES SPOKEN IN ISRAEL

    Oct 1, 2009, 00:00

  • PCN34 BUDGET IMPACT ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) IN BRAZIL

    Oct 1, 2009, 00:00

  • PIN26 CLINICAL AND ECONOMIC IMPACTS OF BACTEREMIA CAUSED BY EXTENDED-SPECTRUM BETA-LACTAMASES PRODUCING ESCHERICHIACOLI IN HONG KONG

    Oct 1, 2009, 00:00

  • PIN41 PREVENTION OF AN INFLUENZA PANDEMIC IN MEXICO- ESTABLISHING A COST-EFFECTIVE ALTERNATIVE FOR ELDERLY POPULATION

    Oct 1, 2009, 00:00

  • PGI1 A STRONG NONLINEAR RELATIONSHIP BETWEEN ADHERENCE WITH DRUG THERAPY AND CONTINUOUS RISK FACTORS IN PPI USERS

    Oct 1, 2009, 00:00

  • PND4 THE FEATURES OF MULTIPLE SCLEROSIS IN IRAN

    Oct 1, 2009, 00:00

  • PCN11 INDIRECT COMPARISON TO ESTIMATE THE EFFICACY OF INTERVENTIONS IN TREATMENT OF METASTATIC RENAL CELL CARCINOMA- A MIXED TREATMENT COMPARISON

    Oct 1, 2009, 00:00

  • PHP5 RISK OF DEATH AND HOSPITAL LENGTH OF STAY ASSOCIATED WITH CLINICAL EVENTS POTENTIALLY CAUSED BY NEUROMUSCULAR BLOCKADE REVERSAL AGENTS

    Oct 1, 2009, 00:00

  • PMS23 COST OF ILLNESS IN AMYOTROPHIC LATERAL SCLEROSIS, MYASTHENIA GRAVIS AND FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY

    Oct 1, 2009, 00:00

  • PDB5 ESTIMACIRDIDA DE PRODUCTIVIDAD POR MORTALIDAD ATRIBUIBLE A LA DIABETES EN ARGENTINA

    Oct 1, 2009, 00:00

  • PRS4 COST OF ILLNESS OF ASHTMA IN A HOSPITAL OF A COLOMBIAN REGION 2006-2009

    Oct 1, 2009, 00:00

  • PSY37 IMPACT OF TOLVAPTAN ON SELF-REPORTED UTILITY SCORES IN HYPONATREMIC PATIENTS

    Oct 1, 2009, 00:00

  • PDB8 SELF-MONITORING OF BLOOD GLUCOSE FOR TYPE 2 DIABETES PATIENTS ON ORAL ANTI-DIABETIC MEDICATION- COSTEFFECTIVENESS IN MEXICO

    Oct 1, 2009, 00:00

  • PSS36 DEVELOPMENT AND VALIDATION OF THE PATIENT-REPORTED IMPACT OF SCARS MEASURE (PRISM)

    Oct 1, 2009, 00:00

  • PHP57 GLOBAL PRICING AND REIMBURSEMENT (P R) TRENDS- FURTHER DEVELOPMENTS IN SUPPLY AND DEMAND SIDE CONTROLS FOR MEDICINES

    Oct 1, 2009, 00:00

  • PMH75 PREDICTORS AND COSTS OF MDD TREATMENT WITH DULOXETINE COMPARED WITH VENLAFAXINE EXTENDED RELEASE

    Oct 1, 2009, 00:00

  • PIN5 UNDERESTIMATION OF VARICELLA INCIDENCE IN THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PIN23 POOR ADHERENCE TO TREATMENT WITH PEGYLATED INTERFERON/ RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION IS ASSOCIATED WITH GREATER HEALTH CARE COSTS

    Oct 1, 2009, 00:00

  • PSY56 SYSTEMATIC REVIEW OF THE DIRECT COSTS RELATED TO OBESITY AND ASSOCIATED DISEASES IN POLAND

    Oct 1, 2009, 00:00

  • PUK4 THE IMPACT ON COSTS OF TREATING COMPLICATIONS DUE TO CRONIC KIDNEY DISEASE IN PATIENTS UNDERGOING HEMODIALYSIS IN THE PUBLIC HEALTH CARE SYSTEM IN BRAZIL

    Oct 1, 2009, 00:00

  • PSY51 THE IMPACT OF OBESITY ON QUALITY OF LIFE IN POLISH POPULATION

    Oct 1, 2009, 00:00

  • PCN3 HEAD AND NECK CANCER PATIENTS AT INCREASED RISK OF COMORBIDITY COMPARED TO CANCER-FREE CONTROLS

    Oct 1, 2009, 00:00

  • PMC59 CULTURAL AND LINGUISTIC ISSUES ASSOCIATED WITH THE TRANSLATION AND LINGUISTIC VALIDATION OF QUESTIONNAIRES FOR USE IN CHINA

    Oct 1, 2009, 00:00

  • PIN11 BUDGET IMPACT ANALYSIS OF NEW ANTRIRETROVIRAL MEDICINES FOR TREATMENT OF HIV PATIENTS IN BULGARIA

    Oct 1, 2009, 00:00

  • PCN149 COST ANALYSIS OF 10-YEARS FOLLOW-UP OF CHEMOTHERAPY REGIMENS WITHIN THE SLOVAK REPUBLIC

    Oct 1, 2009, 00:00

  • PRS8 OPTIMA MODEL-BASED COST-UTILITY ANALYSIS OF FIXED COMBINATIONS SALMETEROL/FLUTICASONE VS. BUDESONIDE/FORMOTEROL IN TREATMENT OF ASTHMA IN RUSSIA

    Oct 1, 2009, 00:00

  • PSS3 A COMPREHENSIVE SYSTEMATIC REVIEW OF THE PSYCHOMETRIC PROPERTIES OF VFQ-25 IN GLAUCOMA

    Oct 1, 2009, 00:00

  • PDB4 LONG-TERM OUTCOMES OF SWITCHING PATIENTS WITH TYPE 2 DIABETES FROM BIPHASIC INSULIN TO BIPHASIC INSULIN ASPART 30/70- AN IMPROVE STUDY SUBGROUP ANALYSIS

    Oct 1, 2009, 00:00

  • PMC5 MEASURING AND MONITORING THE REAL-WORLD COSTEFFECTIVENESS OF NEW TECHNOLOGIES IN HOSPITALS

    Oct 1, 2009, 00:00

  • PND7 BUDGET IMPACT AND COST-EFFECTIVENESS OF SUGAMMADEX IN THE REVERSAL OF PATIENTS WITH NEUROMUSCULAR BLOCK

    Oct 1, 2009, 00:00

  • PMH56 A PATIENT PERSPECTIVE ON SIDE EFFECTS OF ANTIPSYCHOTIC THERAPY- THE TOOL INSTRUMENT

    Oct 1, 2009, 00:00

  • PUK7 ANALYSIS OF THE PHARMACOTHERAPY COST OF PATIENTS WITH KIDNEY TRANSPLANTATION IN BULGARIA

    Oct 1, 2009, 00:00

  • PCV20 THE EFFICACY OF CLOPIDOGREL VERSUS THE COMBINATION OF LOW DOSE ASPIRIN PLUS EXTENDED-RELEASE DIPYRIDAMOLE IN PREVENTING SERIOUS VASCULAR EVENTS- A NETWORK META-ANALYSIS

    Oct 1, 2009, 00:00

  • PIH11 REDUO PAULO

    Oct 1, 2009, 00:00

  • PCN27 TRENDS IN COLORECTAL CANCER SCREENING (CRC) PATTERNS AMONG COMMUNITY DWELLING MEDICARE BENEFICIARIES

    Oct 1, 2009, 00:00

  • PCN17 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 5% CREAM FOR THE TREATMENT OF SUPERFICIAL BASAL CELL CARCINOMA

    Oct 1, 2009, 00:00

  • PMC73 DIFFERENT STUDY RESULTS OF UTILITIES IN RELATION TO THE DOCUMENTING METHOD USED AND THE GUARANTEE OF LEGALLY COMPLIANT IQWIG RECOMMENDATIONS WITHIN THE FRAMEWORK OF A COST-BENEFIT ASSESSMENT

    Oct 1, 2009, 00:00

  • PDB74 ETHICAL DILEMMAS OF PHARMACOLOGICAL TREATMENT AND SELF MANAGEMENT OF DIABETES-A REVIEW OF THE LITERATURE

    Oct 1, 2009, 00:00

  • PCN72 EPIDEMIOLOGICAL AND COST-EFFECTIVENESS ANALYSIS OF THE CROSS PROTECTION DIFFERENCE BETWEEN THE BIVALENT AND THE QUADRIVALENT HPV VACCINES IN FRANCE

    Oct 1, 2009, 00:00

  • PHP17 CAN ELECTRONIC NOTIFICATIONS ABOUT SUBSTITUTES CHANGE PHYSICIANS DRUG PRESCRIPTION HABITS? DEFINITELY YES!

    Oct 1, 2009, 00:00

  • PDB75 APPLICATION OF HTA TO ANTIDIABETIC DRUG FORMULARY DECISIONS

    Oct 1, 2009, 00:00

  • PDB6 EVALUACIN DE LA INSULINA- EL DILEMA DE LOS PAGADORES

    Oct 1, 2009, 00:00

  • PSY58 RIMONABANT IN CLINICAL PRACTICE (RICP). A SWEDISH MULTICENTER SURVEY IN PRIMARY CARE

    Oct 1, 2009, 00:00

  • PCN153 PERFORMANCE MONITORING OF ORGANIZED CANCER SCREENING PROGRAMMES USING ADMINISTRATIVE DATA

    Oct 1, 2009, 00:00

  • EE5 THE SEESAW OF COST-EFFECTIVENESS THRESHOLDS- HOW RELAXED REQUIREMENTS FOR LATER LINES OF TREATMENT WILL INCREASE HURDLES FOR NEW THERAPIES

    Oct 1, 2009, 00:00

  • PIN18 IMPACTO EPIDEMIOLN DE LA VACUNA DE INFLUENZA EN COLOMBIA

    Oct 1, 2009, 00:00

  • PMC54 ESTIMATING SOCIAL PREFERENCES FOR EQ-5D IN TURKEY - A NOVEL METHOD BASED ON A VALUATION EXCHANGE-RATE MECHANISM

    Oct 1, 2009, 00:00

  • PSS43 EVALUATION OF THE IMPLEMENTATION OF UK NATIONAL GUIDANCE ON THE USE OF BIOLOGICS IN SEVERE PSORIASIS

    Oct 1, 2009, 00:00

  • PHP9 AN, BRASIL

    Oct 1, 2009, 00:00

  • PSY47 VALIDATION OF THE FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY (FACIT)-FATIGUE SCALE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

    Oct 1, 2009, 00:00

  • PMC35 SCHIZOPHRENIA MODELING- MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION

    Oct 1, 2009, 00:00

  • PMC62 ONLINE ADMINISTRATION OF THE TIME TRADE-OFF- A CASE-STUDY AMONG PEOPLE WITH RESTLESS LEGS SYNDROME

    Oct 1, 2009, 00:00

  • AC4 A RETROSPECTIVE COHORT STUDY OF MEDICATION ADHERENCE TO TREATMENT OF OSTEOPOROSIS IN A SWEDISH POPULATION

    Oct 1, 2009, 00:00

  • PND13 IMPACT OF CHRONIC (CM) AND EPISODIC MIGRAINE (EM) ON WORK PRESENTEEISM IN 9 COUNTRIES

    Oct 1, 2009, 00:00

  • PIN21 BURDEN AND COST OF SNAKEBITE ENVENOMING- ANTIVENOM OUT OF REACH?

    Oct 1, 2009, 00:00

  • PCN161 REIMBURSEMENT OF ADMINISTRATION COSTS ARE UNAFFECTED BY SINGLE, DOUBLE OR TRIPLE ANTI-CANCER THERAPY COMBINATIONS IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) IN FRANCE AND GERMANY

    Oct 1, 2009, 00:00

  • PND11 NEW ACTIVA PC FAMILY- COST ANALYSIS OF THE NEW FEATURES FOR DEEP BRAIN STIMULATION THERAPY (DBS)

    Oct 1, 2009, 00:00

  • PRS32 ADJUSTING THE NICOTINE DOSE- THE KEY TO A SUCCESSFUL, 'TAILORED' METHOD OF QUITTING SMOKING

    Oct 1, 2009, 00:00

  • PCV30 PRACTICE PATTERNS AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2008- CZECH REPUBLIC BASELINE RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II)

    Oct 1, 2009, 00:00

  • PSY4 ECONOMIC EVALUATION OF METFORMIN, METFORMIN SIBUTRAMIN OR ACARBOSE IN THE MANAGEMENT OF OVERWEIGHT AND OBESE DIABETES PATIENTS

    Oct 1, 2009, 00:00

  • PMC53 A SPECIFIC QUALITY OF LIFE INSTRUMENT FOR PATIENTS WITH HAND-FOOT SYNDROME

    Oct 1, 2009, 00:00

  • PCN95 COST-EFFECTIVENESS OF BEVACIZUMAB COMBINATION THERAPY IN METASTATIC COLORECTAL CANCER- RESULTS OF MARKOV COHORT SIMULATION FROM A SOCIAL PERSPECTIVE IN KOREA

    Oct 1, 2009, 00:00

  • PSS30 ETUD GLAUCOME, ETUDE TRANSVERSALE UN JOUR DANS LE GLAUCOME- ONE-DAY CROSS SECTIONAL STUDY IN GLAUCOMA

    Oct 1, 2009, 00:00

  • PCV57 COSTS OF ATRIAL FIBRILLATION IN SLOVAKIA FROM A PAYER PERSPECTIVE

    Oct 1, 2009, 00:00

  • PCN32 QUALITY OF LIFE IN DIFFERENT STAGES OF MEXICAN BREAST CANCER PATIENTS

    Oct 1, 2009, 00:00

  • PHP9 HELSPORS ASSESSMENT OF THE PHARMACEUTICAL POLICY REFORMS IN GREECE- COST-CONTAINMENT AND ECONOMIC EVALUATION CRITERIA

    Oct 1, 2009, 00:00

  • PMS10 RECURRENT FRACTURES AFTER FIRST HIP FRACTURES POSHIP(PREVENTION OF SECOND HIP FRACTURES) STUDY

    Oct 1, 2009, 00:00

  • PCN144 PATTERNS OF EMPLOYMENT AFTER CANCER- RESULTS OF A LONGITUDINAL STUDY

    Oct 1, 2009, 00:00

  • PSY41 MEASUREMENT OF HEALTH UTILITY VALUES IN THE UK FOR HEALTH STATES RELATED TO IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA (ITP)

    Oct 1, 2009, 00:00

  • PND49 MIGRAINE- PRESCRIBING PATTERNS IN A SOUTH AFRICAN PRIMARY CARE PATIENT POPULATION

    Oct 1, 2009, 00:00

  • PND44 EVALUATION OF THE IMPACT OF PARKINSONS DISEASE SYMPTOMS ON HEALTH-RELATED QUALITY OF LIFE. PD-QOL STUDY

    Oct 1, 2009, 00:00

  • PG120 EFFECT OF SUBCUTANEOUS (SC) METHYLNALTREXONE ON PATIENT REPORTED CONSTIPATION SPECIFIC QUALITY OF LIFE IN A RANDOMIZED DOUBLE-BLIND CLINICAL TRIAL

    Oct 1, 2009, 00:00

  • PCV130 COMPLIANCE (ADHERENCE) TO ANTIHYPERTENSIVE THERAPY IN AUSTRALIA

    Oct 1, 2009, 00:00

  • PMH5 COST-EFFECTIVENESS OF RISPERIDONE LONG-ACTING INJECTABLE VERSUS QUETIAPINE IN SCHIZOPHRENIC PATIENTS

    Oct 1, 2009, 00:00

  • PHP29 UN POUR TOUT, TOUT POUR UN? AN EMPIRICAL ANALYSIS OF PHARMACEUTICAL COVERAGE DECISIONS IN THREE COUNTRIES

    Oct 1, 2009, 00:00

  • PDB53 COMORBID DEPRESSION IN PATIENTS DIAGNOSED WITH TYPE 2 DIABETES (T2DM)- EFFECTS ON WORK PRODUCTIVITY

    Oct 1, 2009, 00:00

  • PG119 PATIENT RELEVANT ASPECTS OF DIAGNOSTIC QUESTIONNAIRES AND THEIR SUBSCALES IN GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD)

    Oct 1, 2009, 00:00

  • PCN38 NUMBER NEEDED TO TREAT (NNT) TO AVOID ONE GASTROINTESTINAL STROMAL TUMOUR (GIST) RECURRENCE IN BRAZIL. COST COMPARISON AND BUDGET IMPACT ANALYSIS OF ADJUVANT TREATMENT WITH IMATINIB

    Oct 1, 2009, 00:00

  • CS14 ASSESSMENT OF THE ECONOMICAL IMPACT OF NON-PERSISTENCE WITH ANTIDEPRESSANT TREATMENTS USING THE ADMINISTRATIVE CLAIMS DATABASE OF QUEBEC (CANADA)

    Oct 1, 2009, 00:00

  • MH1 A DISCRETE EVENT SIMULATION MODEL IN MAJOR DEPRESSIVE DISORDER-COST-EFFECTIVENESS ANALYSIS OF AGOMELATINE

    Oct 1, 2009, 00:00

  • PRS10 THE ECONOMIC IMPLICATION OF EARLY DETECTION OF COPD IN GENERAL PRACTICE IN DENMARK

    Oct 1, 2009, 00:00

  • PHP40 THE CONCENTRATION OF PHARMACEUTICAL MARKET IN SOME MEDICINE GROUPS IN FINLAND

    Oct 1, 2009, 00:00

  • PMS31 COST OF TREATMENT COMPARISON OF TNF- INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN SOUTH AFRICA

    Oct 1, 2009, 00:00

  • PCV7 IMPACTO ECONACA (IC), SOB A PERSPECTIVA DO SISTEMA UNICO DE SAUDE (SUS), NO BRASIL

    Oct 1, 2009, 00:00

  • PMS39 SEQUENTIAL COST-EFFECTIVENESS MODELLING OF DIFFERENT BIOLOGIC STRATEGIES IN RHEUMATOID ARTHRITIS IN TURKEY

    Oct 1, 2009, 00:00

  • PHP79 A REVIEW OF THE USE OF PROS IN SUBMISSIONS TO NICE

    Oct 1, 2009, 00:00

  • PRS15 NEW PHARMACOECONOMIC MODEL OF ASTHMA MAINTENANCE TREATMENT (OPTIMA) IN RUSSIA. TO TREAT OR NOT TO TREAT- MAINTENANCE TREATMENT VS. NO MAINTENANCE TREATMENT

    Oct 1, 2009, 00:00

  • PCN116 A SURVIVAL BASED COST-EFFECTIVENESS ANALYSIS OF 5 YEARS LETROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER- CANADIAN PERSPECTIVE

    Oct 1, 2009, 00:00

  • HP4 INFLUDE

    Oct 1, 2009, 00:00

  • PDB64 A RETROSPECTIVE DATABASE ANALYSIS OF PERSISTENCE WITH INSULIN IN PATIENTS WITH TYPE 2 DIABETES ADDING MEALTIME INSULIN TO A BASAL REGIMEN

    Oct 1, 2009, 00:00

  • PCV14 A COMPARISON OF BLOOD PRESSURE OUTCOMES ASSOCIATED WITH THE USE OF ANGIOTENSIN-RECEPTOR BLOCKERS (ARBS) IN PATIENTS SEEN PREDOMINANTLY IN PRIMARY CARE PRACTICES

    Oct 1, 2009, 00:00

  • PHP10 GERENCIAMENTO DE DOENDE?

    Oct 1, 2009, 00:00

  • PCN25 HALF OF BREAST CANCER PATIENTS STARTING ON TAMOXIFEN COMPLETE FIVE YEARS OF ENDOCRINE TREATMENT

    Oct 1, 2009, 00:00

  • CS19 AUDITORIA BASEADA EM EVIDO

    Oct 1, 2009, 00:00

  • PDB55 LINGUISTIC VALIDATION, INCLUDING CULTURAL ADAPTATION, OF AN UPDATED ADKNOWL, DIABETES KNOWLEDGE QUESTIONNAIRE, FOR INTERNATIONAL USE

    Oct 1, 2009, 00:00

  • PSY14 COST-EFFECTIVENESS AND BUDGET IMPACT OF LOW DOSE 7-DAY BUPRENORPHINE PATCH FOR MODERATE TO SEVERE OSTEOARTHRITIS PAIN IN THE CONTEXT OF KOREA NATIONAL HEALTH INSURANCE

    Oct 1, 2009, 00:00

  • PIN59 POTENTIAL ECONOMIC IMPACT OF OUTPATIENT CARBAPENEM TREATMENT FOR BACTERAEMIA CAUSED BY ESBL-PRODUCING BACTERIA IN HONG KONG-A DECISION ANALYSIS

    Oct 1, 2009, 00:00

  • PHP43 INTERNATIONAL PAYER RESARCH- COMPARING AND CONTRASTING PAYER ROLES AND RESEARCH METHODS IN CANADA, SPAIN, AND THE UK

    Oct 1, 2009, 00:00

  • PCV92 COST-EFFECTIVENESS OF AN EXERCISE TRAINING PROGRAM IN HEART FAILURE

    Oct 1, 2009, 00:00

  • PMH7 EFFICACY OF ANTIPSYCHOTICS IN THE PREVENTION OF SCHIZOPHRENIA RELAPSE- A SYSTEMATIC REVIEW OF DOUBLE BLIND RANDOMISED CONTROLLED TRIALS

    Oct 1, 2009, 00:00

  • PCV122 ANGIOGRAPHY FOR DIAGNOSING PAOD- COST COMPARISON OF THE DIAGNOSTIC PROCEDURES MRA AND DSA

    Oct 1, 2009, 00:00

  • PCV131 NONADHERENCE AND DISCONTINUATION OF LOW-DOSE ACETYLSALICYLIC ACID IN PATIENTS WITH CARDIOVASCULAR RISK- THE IMPACT OF GASTROINTESTINAL SYMPTOMS

    Oct 1, 2009, 00:00

  • CASE3 INSTRUMENTOS FINANCIEROS Y VIABILIDAD SECTORIAL

    Oct 1, 2009, 00:00

  • PIN10 A BUDGET IMPACT MODEL TO ESTIMATE THE ECONOMIC IMPACT OF ITRACONAZOLE IN PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH NEUTROPENIA IN SPAIN

    Oct 1, 2009, 00:00

  • PCN163 RURAL-URBAN DIFFERENCES IN COLORECTAL CANCER HOSPITALIZATIONS IN WEST VIRGINIA, USA

    Oct 1, 2009, 00:00

  • PCN46 COST SAVINGS RELATED TO SUPERIOR ADVERSE EVENT PROFILE OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY- A SENSITIVITY ANA ...

    Oct 1, 2009, 00:00

  • PHP66 COST-EFFECTIVENESS RESEARCH ON PREVENTIVE MEASURES- A SURVEY OF THE PUBLICATIONS IN 2008

    Oct 1, 2009, 00:00

  • PDB18 COST OFFSETS ASSOCIATED WITH USE OF EXENATIDE COMPARED TO GLARGINE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2009, 00:00

  • PCV168 COMMUNITY PHARMACY DISPENSING OF PRESCRIPTION MEDICINE SAMPLE PACKS-CHANGING THE BUSINESS OF MEDICINE INITIATION?

    Oct 1, 2009, 00:00

  • PMC60 WILLINGNESS TO PAY FOR HEALTH INTERVENTIONS- BASED ON SYSTEMATIC REVIEW OF LITERATURES

    Oct 1, 2009, 00:00

  • PIH7 MORTALITY ACCORDING TO THE DAY OF ADMISSION IN INTENSIVE CARE UNITS AND MATERNITY WARDS IN HUNGARY

    Oct 1, 2009, 00:00

  • PMH14 ALZHEIMERS DISEASE- A PHARMACOEPIDEMIOLOGICAL STUDY

    Oct 1, 2009, 00:00

  • PDB28 THE COST-EFFECTIVENESS ANALYSIS OF VIDALGLIPTIN IN TYPE 2 DIABETES IN POLAND

    Oct 1, 2009, 00:00

  • PG13 INTRAVENOUS (IV) PROTON PUMP INHIBITORS (PPIS) FOR THE TREATMENT OF PEPTIC ULCER BLEEDING (PUB)

    Oct 1, 2009, 00:00

  • PCN45 COST COMPARISON BETWEEN 90Y IBRITUMOMAB TIUXETAN CONSOLIDATION AND RITUXIMAB MAINTENANCE POST-CHEMOTHERAPY IN NAS LYMPHOMA IN SPAIN

    Oct 1, 2009, 00:00

  • PRS5 PRIMARY CARE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS FROM GENERAL PRACTICE DATABASE

    Oct 1, 2009, 00:00

  • PCN111 COST MINIMIZATION ANALYSIS FOR STAPLED VERSUS HANDSEWN SURGERY TECHNIQUES FOR ANASTOMOSES IN SURGICAL TREATMENT FOR COLON CANCER, UNDER THE BRAZILIAN PUBLIC PAYER PERSPECTIVE

    Oct 1, 2009, 00:00

  • PCV2 INCREASED RISK OF MORTALITY AND CO-MORBIDITIES IN PATIENTS WITH UNTREATED PRIMARY HYPERPARATHYROIDISM

    Oct 1, 2009, 00:00

  • PCN31 A DESCRIPTIVE ANALYSIS OF THE ASSOCIATION BETWEEN BREAST CANCER RISK, BONE MINERAL DENSITY AND FRACTURES IN POST-MENOPAUSAL WOMEN IN THE CANADIAN MULTICENTRE OSTEOPOROSIS STUDY

    Oct 1, 2009, 00:00

  • PCN4 ERYTHROPOIESIS STIMULATING AGENTS (ESA) FOR THE TREATMENT OF CHEMOTHERAPY INDUCED ANEMIA IN PATIENTS WITH HEMOGLOBIN LEVELS (HB) 11G/DL-A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2009, 00:00

  • PCN107 COST-EFFECTIVENESS OF HPV VACCINATION-AN OVERVIEW ON INTERNATIONAL STUDY RESULTS

    Oct 1, 2009, 00:00

  • PIN7 COSTO-BENEFICIO DEL USO DE TIGECICLINA VS. TRIPLE ESQUEMA ANTIMICROBIANO CEFOTAXIMA/AMIKACINA/METRONIDAZOL EN PACIENTES CON INFECCIONES INTRAABDOMINALES Y DE PIEL Y TEJIDOS BLANDOS EN MXICO

    Oct 1, 2009, 00:00

  • PMS16 BUDGET IMPACT ANALYSIS OF TOCILIZUMAB UNDER THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2009, 00:00

  • PCASE3 GESTDE

    Oct 1, 2009, 00:00

  • PDB48 ASSESSING THE MINIMUM CLINICALLY IMPORTANT DIFFERENCE OF THE WORRY SCALE OF THE HYPOGLYCAEMIA FEAR SURVEY IN PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2009, 00:00

  • PIN71 QUALITY OF LIFE (QOL) AND OTHER ENDPOINTS COMPARISON IN THE TREATMENT OF FACIAL LIPOATROPHY WITH INJECTION OF POLY-L-LACTIC ACID

    Oct 1, 2009, 00:00

  • PCV161 HEALTH CARE RESOURCES UTILIZATION IN ACUTE CORONARY SYNDROME PATIENTS ONE YEAR AFTER PCI - FRENCH RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY (APTOR)

    Oct 1, 2009, 00:00

  • PIN35 CLINICAL AND ECONOMIC BENEFITS OF NATIONAL IMMUNIZATION WITH THE 13-VALENT COMPARED TO 7- AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN GREECE

    Oct 1, 2009, 00:00

  • PMH27 COMPARISON OF COST FOR DIFFERENT TESTS OF DEMENTIA SCREENING

    Oct 1, 2009, 00:00

  • PDB70 ORAL MEDICATIONS VS INSULIN FOR DIABETES- EPIDEMIOLOGICAL HEALTH POLICY IMPLICATIONS IN GREECE

    Oct 1, 2009, 00:00

  • PCV18 COSTO-EFECTIVIDAD DE ETEXILATO DE DABIGATRAN EN LA PROFILAXIS DE LA ENFERMEDAD TROMBOEMBOLICA VENOSA (ETV) ASOCIADA CON CIRUGIA DE CADERA EN EL PACIENTE ADULTO EN EL INSTITUTO MEXICANO DEL SEGURO SOCIAL (IMSS)

    Oct 1, 2009, 00:00

  • PRS46 OFF-LABEL PRESCRIBING OF INHALED CORTICOSTEROID/ LONG ACTING BETA-AGONIST COMBINATION PRODUCTS IN COPD PATIENTS

    Oct 1, 2009, 00:00

  • PCN28 INCIDENCE AND PREVALENCE OF CUTANEOUS MELANOMA IN FRANCE- A POPULATION BASED STUDY FROM EIGHT CANCER REGISTRIES

    Oct 1, 2009, 00:00

  • PMS64 ANALYSIS OF HOSPITAL EVENTS MEANING IATROGENICITY, ANHEMIA

    Oct 1, 2009, 00:00

  • PR7 EVALUATION OF ALTERNATIVE METHODS OF TRANSLATING PATIENT-REPORTED OUTCOME MEASURES

    Oct 1, 2009, 00:00

  • PDB54 ASSESSING THE BURDEN OF ACROMEGALY- A REVIEW OF HEALTH-RELATED QUALITY OF LIFE AND ECONOMICS

    Oct 1, 2009, 00:00

  • PMS25 MEDICAL RESOURCE UTILIZATION AND WORKDAYS LOST IN PATIENTS WITH FIBROMYALGIA

    Oct 1, 2009, 00:00

  • VA1 SEVEN, TEN OR THIRTEEN? THE COST-UTILITY OF INFANT VACCINATION WITH A 7-, 10- OR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PIN75 ECONOMIC IMPACT OF NEW MALARIA DIAGNOSTIC DEVICES ON THE MALARIA CONTROL PROGRAM IN BRAZIL

    Oct 1, 2009, 00:00

  • PIN6 COSTS OF NOSOCOMIAL PNEUMONIA IN A THIRD LEVEL HOSPITAL OF MEXICAN SOCIAL SECURITY INSTITUTE (IMSS)

    Oct 1, 2009, 00:00

  • PRS42 VALIDATION OF THE SPANISH VERSION OF THE 'COPD AND ASTHMA FATIGUE SCALE (CAFS)' QUESTIONNAIRE

    Oct 1, 2009, 00:00

  • PCV155 IMPACT OF EXPANDING PHARMACY BENEFITS ON TREATMENT OF CONGESTIVE HEART FAILURE- THE CASE OF MEDICARE PART D

    Oct 1, 2009, 00:00

  • PCV25 THE EFFECT OF ANTI-ARRHYTHMIC DRUG THERAPY ON ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN ATRIAL FIBRILLATION PATIENTS- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2009, 00:00

  • PCV11 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT OR TOTAL KNEE REPLACEMENT IN COLOMBIA

    Oct 1, 2009, 00:00

  • PSY31 COST-MINIMIZATION ANALYSIS COMPARING 5% AND 10% INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS IN THE TREATMENT OF PRIMARY IMMUNE DEFICIENCY

    Oct 1, 2009, 00:00

  • PSS41 DEVELOPMENT AND ACCEPTABILITY OF A NEW INTERNATIONAL QUALITY OF LIFE INSTRUMENT SPECIFIC TO PHYSICAL APPEARANCE- BEAUTYQOL

    Oct 1, 2009, 00:00

  • PHP15 BIOSIMILARS- HGH TO TNFS, HOW WILL PAYERS RESPOND?

    Oct 1, 2009, 00:00

  • PMC8 USING ATLAS.TI AS A TOOL TO EXTRACT AND SYNTHESIZE DATA OBTAINED IN LITERATURE REVIEWING

    Oct 1, 2009, 00:00

  • PIH42 RESULTS OF AN OBSERVATIONAL STUDY IN 574 COMMUNITY PHARMACIES IN SPAIN CHARACTERIZING PATIENT PROFILES OF MEN ASKING FOR ERECTILE DYSFUNCTION MEDICATION

    Oct 1, 2009, 00:00

  • MC4 COMPARISON OF DATA AVAILABILITY AND QUALITY FOR PHARMACOECONOMIC ANALYSIS IN BRAZIL VERSUS THE UNITED STATES AND EUROPEAN UNION- THE CASES OF DIABETES HYPERTENSION

    Oct 1, 2009, 00:00

  • PMH8 FACTORES ASOCIADOS AL INCUMPLIMIENTO DE TRATAMIENTOS CON ANTIDEPRESIVOS EN SANTIAGO, CHILE

    Oct 1, 2009, 00:00

  • PCV87 COST-EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND PLANNED PCI- RESULTS FROM THE TRITON-TIMI 38 TRIAL FROM THE GERMAN PERSPECTIVE

    Oct 1, 2009, 00:00

  • PCN142 EVALUATION OF THE QUALITY OF LIFE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WHO FAILED TO FIRST LINE CHEMOTHERAPY IN TREATMENT WITH ERLOTINIB VS TAXANES

    Oct 1, 2009, 00:00

  • PHP22 TOO MANY AGENCIES FOR DRUG EVALUATION IN SPAIN?

    Oct 1, 2009, 00:00

  • PRS49 FACTORS RELATED TO STOP SMOKINGS ATTEMPTS AMONG A FRENCH COHORT OF SMOKERS- (FOCUS STUDY)

    Oct 1, 2009, 00:00

  • PIN20 LONG-TERM CONSEQUENCES OF AN INTENSE RUBELLA VACCINATION PROGRAM IN FORTALEZA, BRAZIL- A COST-EFFECTIVENESS ANALYSIS

    Oct 1, 2009, 00:00

  • PDB59 USING THE ECHO MODEL TO EXAMINE THE EFFECT OF AN EMPLOYER-SPONSORED PHARMACIST PROVIDED DIABETES MTM PROGRAM ON OUTCOMES

    Oct 1, 2009, 00:00

  • PCN141 QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) FROM THE AVADO STUDY- THE IMPORTANCE OF IMPUTATION METHODS FOR HANDLING MISSING DATA

    Oct 1, 2009, 00:00

  • PMS7 COST-EFFECTIVENESS OF COLLAGEN-POLYVINYLPYRROLIDONE IN THE TREATMENT OF STABLE NONUNION TIBIAL FRACTURES

    Oct 1, 2009, 00:00

  • PCV148 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HYPERCHOLESTEROLEMIA

    Oct 1, 2009, 00:00

  • PDB3 RESOURCE USE AND DIRECT MEDICAL COSTS ASSOCIATED TO ACROMEGALY TREATMENT UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE

    Oct 1, 2009, 00:00

  • PIH1 MEDICAMENTOS POTENCIALMENTE INAPROPIADOS EN ADULTOS MAYORES ATENDIDOS EN ATENCIN PRIMARIA DE SALUD

    Oct 1, 2009, 00:00

  • PG15 PREDICTORS FOR RESPONSE TO PRUCALOPRIDE IN PATIENTS WITH CHRONIC CONSTIPATION

    Oct 1, 2009, 00:00

  • PMC71 THE EVOLVING HEALTH ECONOMICS EVALUATION PARADIGM AND THE ROLE OF THE QALY

    Oct 1, 2009, 00:00

  • PND24 TREATMENT OF ADVANCED PARKINSONS DISEASE IN THE UNITED STATES- A COST-UTILITY MODEL

    Oct 1, 2009, 00:00

  • PCN87 A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

    Oct 1, 2009, 00:00

  • PDB1 COSTS OF INSULIN GLARGINE AND INSULIN DETEMIR IN INTENSIVE INSULIN THERAPY FOR TYPE 1 DIABETES MELLITUS IN ARGENTINA- A PROBABILISTIC MODEL

    Oct 1, 2009, 00:00

  • PIN62 COST-EFFECTIVENESS OF TARGETED SCREENING FOR HEPATITIS C IN THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PCN135 USING THE FACT-LEUKEMIA SUBSCALE TO EVALUATE QUALITY OF LIFE IN LEUKEMIA PATIENTS WORLDWIDE

    Oct 1, 2009, 00:00

  • PMH76 PREDICTORS FOR DULOXETINE TREATMENT FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN VETERANS AFFAIRS HEALTH CARE NETWORK

    Oct 1, 2009, 00:00

  • PCV123 COST OF ARTERIAL HYPERTENSION ACCORDING TO LEVELS OF MORBIDITY IN PRIMARY CARE SETTING

    Oct 1, 2009, 00:00

  • PCN156 EFFECTS OF PHARMACEUTICAL INNOVATION AND DEMOGRAPHIC CHANGE ON THE GERMAN ONCOLOGY MARKET

    Oct 1, 2009, 00:00

  • PDB24 COST EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO BIPHASIC INSULIN ASPART 30 FROM BIPHASIC HUMAN INSULIN 30 IN THE CZECH SETTING

    Oct 1, 2009, 00:00

  • VA7 COMPARISON OF DIFFERENT STATIC AND DYNAMIC SIMULATION TECHNIQUES FOR THE INFLUENCE OF CHILDREN PNEUMOCOCCAL VACCINATION

    Oct 1, 2009, 00:00

  • PIN55 COST-EFFECTIVENESS OF THE SURVIVING SEPSIS CAMPAIGN PROTOCOL FOR SEVERE SEPSIS IN SPAIN

    Oct 1, 2009, 00:00

  • PG11 A RECORD-LINKAGE STUDY OF ADVERSE UPPER GASTRO-INTESTINAL EVENTS WITH NSAIDS IN A UK POPULATION UTILISING DIFFERENT EPIDEMIOLOGICAL DESIGNS TO MINIMISE CONFOUNDING

    Oct 1, 2009, 00:00

  • PMC57 TO MAP OR NOT TO MAP? THE OXFORD HIP SCORE AND EQ-5D COMPARED

    Oct 1, 2009, 00:00

  • PMC44 MODELLING THE UPTAKE AND DIFFUSION OF INNOVATIVE TECHNOLOGY- A CRITICAL AND STRATEGIC FEATURE OF BUDGET IMPACT ANALYSIS AND RISK-SHARING AGREEMENTS

    Oct 1, 2009, 00:00

  • MC6 SCHIZOPHRENIA MODELING- MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION

    Oct 1, 2009, 00:00

  • PSY12 ECONOMIC AND CLINICAL EFFICACY BENEFITS OF THE USE OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE

    Oct 1, 2009, 00:00

  • PCN48 COST OF CARE FOR COLORECTAL CANCER IN IRELAND- A HEALTH CARE PAYER PERSPECTIVE

    Oct 1, 2009, 00:00

  • PMC51 PATIENT COMPLETION OF EPROS- TO PHONE OR TO WEB?

    Oct 1, 2009, 00:00

  • PCV58 THE DIAGNOSTIC BENEFIT OF STRESS TEST PRIOR TO CARDIAC MULTI-SLICE COMPUTED TOMOGRAPHY IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE- CLINIC AND ECONOMIC OUTCOMES FROM THE EMILIA-ROMAGNA MSCT REGISTRY

    Oct 1, 2009, 00:00

  • PDB65 REAL-LIFE PRESCRIPTION PATTERNS SHOW FEWER TREATMENT CHANGES WITH BASAL INSULIN ANALOGS COMPARED TO NPH IN TYPE 2 DIABETES IN THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PCN53 COST PER DISEASE STAGE OF ADVANCED GASTRIC CANCER IN BRAZIL FROM THE PRIVATE PAYER PERSPECTIVE

    Oct 1, 2009, 00:00

  • PHP7 BED OCCUPANCY RATE OF HUNGARIAN INTENSIVE CARE UNITS

    Oct 1, 2009, 00:00

  • PND28 ADHERENCE AS A PREDICTOR OF THE UTILIZATION OF HEALTH CARE RESOURCES IN A MULTIPLE SCLEROSIS POPULATION USING INTERFERONS

    Oct 1, 2009, 00:00

  • PSS14 A PATIENT SURVEY/CHART REVIEW STUDY ABOUT TREATMENT PATTERNS, COSTS AND QUALITY OF LIFE IN PATIENTS WITH PSORIASIS IN SWEDEN

    Oct 1, 2009, 00:00

  • PCV146 HAS THE TYPE OF ATRIAL FIBRILLATION DIFFERENT IMPACT ON HRQOL?

    Oct 1, 2009, 00:00

  • PDB43 MEDICATION ADHERENCE IN LOW INCOME ELDERLY TYPE 2 DIABETES PATIENTS- A RETROSPECTIVE COHORT STUDY

    Oct 1, 2009, 00:00

  • PCV160 REAL-WORLD PRACTICE PATTERNS OF ACUTE CORONARY SYNDROME (ACS) PATIENTS WITH AND WITHOUT DIABETES MELLITUS (DM)

    Oct 1, 2009, 00:00

  • PIN22 QU FACTORES DETERMINAN LOS PRECIOS INTERNACIONALES DE LOS MEDICAMENTOS ANTIRETROVIRALES?

    Oct 1, 2009, 00:00

  • PMH10 ANRIO TRATAR)

    Oct 1, 2009, 00:00

  • PMC24 SAMPSON- A HYBRID SIMULATION AND OPTIMIZATION MODEL FOR MANAGING SURGICAL RESOURCES AND REDUCING WAITING TIMES

    Oct 1, 2009, 00:00

  • PIH2 USO DE MEDICAMENTOS POTENCIALMENTE INAPROPIADOS EN PACIENTES ANCIANOS HOSPITALIZADOS EN MEDICINA INTERNA DE UN HOSPITAL UNIVERSITARIO

    Oct 1, 2009, 00:00

  • PCV51 THE POTENTIAL ECONOMIC IMPACT OF RECONFIGURING TIA CARE IN ITALY

    Oct 1, 2009, 00:00

  • PSS31 LEVELS OF EMPOWERMENT AMONG PSORIATIC PATIENTS

    Oct 1, 2009, 00:00

  • PDB58 THE 'WHO, HOW AND THEN WHAT' OF INSULIN INITIATION IN UK PRIMARY CARE

    Oct 1, 2009, 00:00

  • PCN89 A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC ...

    Oct 1, 2009, 00:00

  • PCV153 MARYLAND MENS CARDIOVASCULAR PROMOTION-MVP

    Oct 1, 2009, 00:00

  • PRS38 ASSOCIATION BETWEEN SMOKING AND HEALTH-RELATED QUALITY OF LIFE

    Oct 1, 2009, 00:00

  • MC8 COMPARISON OF METHODS- FOR IDENTIFYING DEPRESSION IN PATIENTS WITH DIABETES USING PHYSIOLOGIC, SOCIAL, AND DISEASE SEVERITY MEASURES

    Oct 1, 2009, 00:00

  • PSY9 ADHERENCE TO DULOXETINE THERAPY AND HEALTH CARE COSTS AMONG PATIENTS WITH FIBROMYALGIA

    Oct 1, 2009, 00:00

  • PRS44 CLINICO-PHARMACOLOGICAL PRESENTATION AND THE OUTCOME OF QUALITY OF LIFE OF PATIENTS WITH EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Oct 1, 2009, 00:00

  • PMC48 A DYNAMIC MODEL TO MAXIMIZE THE HELATH BENEFITS IN MUTUALLY EXCLUSIVE SUSCEPTIBLE INFECTIOUS POPULATION

    Oct 1, 2009, 00:00

  • PMS79 IS BODY-MASS-INDEX A PREDICTIVE FACTOR FOR CLINICAL OUTCOME IN PATIENTS WITH MONOSEGMENTAL LUMBAR FUSION?

    Oct 1, 2009, 00:00

  • PCN165 SYSTEMATIC REVIEW OF PUBLISHED META-ANALYSES, SYSTEMATIC REVIEWS, AND HEALTH TECHNOLOGY ASSESSMENTS OF RITUXIMAB FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA

    Oct 1, 2009, 00:00

  • PMH25 CLINICAL AND ECONOMIC CONSEQUENCES OF MEDICATION NONADHERENCE IN THE TREATMENT OF PATIENTS WITH A MANIC/ MIXED EPISODE OF BIPOLAR DISORDER- RESULTS FROM THE EUROPEAN MANIA IN BIPOLAR LONGITUDINAL EVALUATION OF MEDICATION (EMBLEM) STUD ...

    Oct 1, 2009, 00:00

  • PMH39 COST-EFFECTIVENESS OF PREGABALIN VERSUS USUAL CARE IN REFRACTORY OUT-PATIENTS WITH GENERALIZED ANXIETY DISORDER- A NESTED-CASE-CONTROL ECONOMIC EVALUATION UNDER USUAL MEDICAL PRACTICE IN MENTAL HEALTH CENTERS

    Oct 1, 2009, 00:00

  • PRS34 ITEM SELECTION AND SCORING DEFINITION OF A DISEASE-SPECIFIC INSTRUMENT TO ASSESS THE HANDICAP IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS, FOR USE IN CLINICAL ROUTINE PRACTICE

    Oct 1, 2009, 00:00

  • PCN16 THE COST AND HEALTH CONSEQUENCES OF DIFFERENT BREAST CANCER SCREENING STRATEGIES IN COLOMBIA

    Oct 1, 2009, 00:00

  • PIH16 ECONOMIC EVALUATION OF TWO ALTERNATIVE TREATMENTS FOR OVARIAN STIMULATION IN ASSISTED REPRODUCTION

    Oct 1, 2009, 00:00

  • PIH7 COST OF PNEUMONIA HOSPITALIZATION IN ELDERLY PEOPLE FROM TWO LARGE BRAZILIAN HOSPITALS

    Oct 1, 2009, 00:00

  • CS12 IMPACTO EPIDEMIOLN DE LA VACUNA DE HEPATITIS A EN COLOMBIA

    Oct 1, 2009, 00:00

  • PCV138 COMPARATIVE RESEARCH BETWEEN ORAL AND SUBCUTANEOUS THROMBOPROPHYLAXIS- THE STOPWATCH PROJECT

    Oct 1, 2009, 00:00

  • PHP11 DOES PHARMACEUTICAL CONSUMPTION IMPROVE HEALTH CARE STATUS?

    Oct 1, 2009, 00:00

  • PCN29 PATTERNS OF COLORECTAL CANCER SCREENING AND OBESITY AMONG MEDICARE BENEFICIARIES

    Oct 1, 2009, 00:00

  • PMC6 THE NATURE AND SCALE OF INADEQUATE REPORTING OF CONTINUOUS OUTCOMES FROM FOUR SYSTEMATIC REVIEWS

    Oct 1, 2009, 00:00

  • PMS4 COSTO-EFECTIVIDAD DEL USO DE ETANERCEPT VS LOS ANTICUERPOS MONOCLONALES ANTI-TNF EN PACIENTES CON ARTRITIS REUMATOIDE EN COSTA RICA

    Oct 1, 2009, 00:00

  • PUK2 EFFECTIVENESS AND COST-EFFICACY OF PHOSPHATBINDERS IN HEMODIALYSIS

    Oct 1, 2009, 00:00

  • PCN83 COST-EFFECTIVENESS ANALYSIS OF HISTAMINE DIHYDROCHLORIDE + LOW DOSE INTERLEUKIN-2 VS STANDARD OF CARE FOR ACUTE MYELOID LEUKEMIA PATIENTS IN THEIR FIRST COMPLETE REMISSION- A UK PERSPECTIVE

    Oct 1, 2009, 00:00

  • PSS5 RESTOR VERSUS ACRILISA - ND-YAG LASER INCIDENCE RATE COMPARISON 18 MONTHS AFTER SURGERY

    Oct 1, 2009, 00:00

  • PDB30 CSII COMPARED TO MDI- A HEALTH ECONOMIC ANALYSIS IN THE GERMAN HEALTH CARE SETTING

    Oct 1, 2009, 00:00

  • PMS78 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS

    Oct 1, 2009, 00:00

  • PCV105 COST-EFFECTIVENESS OF GENEOTYPE-GUIDED DOSING OF SHORTTERM USE OF WARFARIN AMONG DVT/PE PATIENTS

    Oct 1, 2009, 00:00

  • PHP39 COST MEASURE IN PRIMARY CARE- RETROSPECTIVE BEHAVIOUR OF ACG CASE-MIX SYSTEM AT A SPANISH INTERREGIONAL LEVEL

    Oct 1, 2009, 00:00

  • PDB17 TREATMENT COSTS ATTRIBUTABLE TO BEING OVERWEIGHT OR OBESE IN U.S. DIABETIC PATIENTS- QUANTILE REGRESSION APPROACH

    Oct 1, 2009, 00:00

  • HP5 PROFILE OF HTA USERS AND APPLICABILITY OF HTA REPORTS TO INFORM DECISIONS IN LATIN-AMERICA

    Oct 1, 2009, 00:00

  • PMC66 THE ADVANTAGES OF A CENTRALIZED DISSEMINATION STRATEGY FOR HEALTH OUTCOMES INSTRUMENTS AND THEIR TRANSLATIONS- A CASE EXAMPLE WITH THE ZARIT BURDEN INTERVIEW (ZBI)

    Oct 1, 2009, 00:00

  • PDB68 A RETROSPECTIVE ANALYSIS OF MEDICATION USE, RESOURCE UTILIZATION, AND CLINICAL EFFECTIVENESS OF EXENATIDE COMPARED TO GLARGINE IN PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2009, 00:00

  • CO3 HOW AND WHY AUTOMATED MEDICAL DATABASES SHOULD BE USED TO CREATE BACKGROUND OCCURRENCES FOR DRUG OUTCOMES AND SAFETY STUDIES- GLAUCOMA IN THIN (UK)

    Oct 1, 2009, 00:00

  • PHP37 SOCIAL HEALTH INSURANCE, PREVENTIVE CARE AND HEALTH CARE EXPENDITURE

    Oct 1, 2009, 00:00

  • PSS6 CONJUNCTIVAL HYPERAEMIA ASSOCIATED WITH THE FIXED COMBINATIONS OF LATANOPROST/TIMOLOL AND BIMATOPROST/ TIMOLOL IN THE TREATMENT OF OCULAR HYPERTENSION OR GLAUCOMA

    Oct 1, 2009, 00:00

  • PCN8 EVALUACI, COLOMBIA

    Oct 1, 2009, 00:00

  • PCN88 AN ECONOMIC EVALUATION OF RITUXIMAB VERSUS OTHER FIRST-LINE TREATMENTS FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN POLAND

    Oct 1, 2009, 00:00

  • PIN76 THE PREVALENCE, MORTALITY, AND COST OF CENTRAL LINE BLOOD STREAM INFECTIONS (CLABSI) IN US COMMUNITY HOSPITALS- 2002 TO 2006

    Oct 1, 2009, 00:00

  • PMH36 MENTAL HEALTH COSTS INCURRED BY PATIENTS DIAGNOSED WITH MAJOR DEPRESSIVE DISORDER WHO DO NOT RESPOND TO SUCCESSIVE LINES OF TREATMENT

    Oct 1, 2009, 00:00

  • PCV21 SELF-REPORTED GENERAL HEALTH WAS THE MOST INFLUENTIAL VARIABLE OF EQ-5D SOCIAL PREFERENCES SCORES IN A GENERAL POPULATION SURVEY IN ARGENTINA, AND ITS INFLUENCE DIFFERED ACCORDING TO GENDER, AGE AND INCOME STATUS

    Oct 1, 2009, 00:00

  • PCV114 DABIGATRAN ETEXILATE IS COST-SAVING FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS FOLLOWING MAJOR ORTHOPAEDIC SURGERY IN THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PDB12 GLYCATED HAEMOGLOBIN AS A SURROGATE MARKER FOR THE APPEARANCE AND PROGRESSION OF RETINOPATHY IN TYPE-1 DIABETES MELLITUS- SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2009, 00:00

  • PMS60 COST-UTILITY OF EXERCISE THERAPY IN ADOLESCENTS AND YOUNG ADULTS SUFFERING FROM THE PATELLOFEMORAL PAIN SYNDROME

    Oct 1, 2009, 00:00

  • MO12 COMPARISON OF THREE META-MODELS FOR UNCERTAINTY ANALYSIS

    Oct 1, 2009, 00:00

  • PCV91 COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN AS ADJUNCTIVE THERAPY WITH FIBRINOLYSIS IN SPANISH PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION (STEMI)- RESULTS FROM EXTRACT-TIMI 25

    Oct 1, 2009, 00:00

  • PDB10 COST-MINIMIZATION ANALYSIS COMPARING INSULIN GLARGINE TO INSULIN DETEMIR IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS IN BRAZIL

    Oct 1, 2009, 00:00

  • PHP21 THE ROLE OF MONETARY AND NON-MONETARY INCENTIVES ON THE CHOICE OF PRACTICE ESTABLISHMENT- A STATED PREFERENCE STUDY OF YOUNG PHYSICIANS IN GERMANY

    Oct 1, 2009, 00:00

  • PMC1 CORRECTING AN UNDERESTIMATE OF INCREMENTAL COST EFFECTIVENESS RATIO CONSIDERING STATISTICAL ERRORS AND PROBABILITY OF TRUTH

    Oct 1, 2009, 00:00

  • PUK1 CONHECIMENTO DO RISCO DA DOENNICA NO GRUPO DE RISCO

    Oct 1, 2009, 00:00

  • PMH37 COST-EFFECTIVENESS OF PREGABALIN VERSUS USUAL CARE IN DULOXETINE-REFRACTORY OUT-PATIENTS WITH GENERALIZED ANXIETY DISORDER- AN ECONOMIC EVALUATION UNDER MEDICAL USUAL PRACTICE IN MENTAL HEALTH CENTERS

    Oct 1, 2009, 00:00

  • PIN30 USE OF NET-BENEFIT REGRESSION FRAMEWORK TO INVESTIGATE THE COST-EFFECTIVENESS OF COMBINATION ANTIVIRAL THERAPY AMONG HCV-INFECTED PATIENTS ENROLLED IN A MANAGED CARE ORGANIZATION

    Oct 1, 2009, 00:00

  • PHP95 MEDICAL FOODS AND FOODS FOR SPECIAL MEDICAL PURPOSES

    Oct 1, 2009, 00:00

  • PUK11 COST-MINIMIZATION ANALYSIS- MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA) VS. ARANESP (DARBEPOETIN ALFA) IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) WHO ARE NOT RECEIVING HAEMODIALYSIS, IN POLISH SETTING

    Oct 1, 2009, 00:00

  • CN8 METHODOLOGICAL ISSUES OF CONTROL ARM ADJUSTMENTS FOR COMPARATIVE EFFECTIVENESS ASSESSMENTS- AN EXAMPLE BASED ON THE COMPARISON OF FIRST-LINE BEVACIZUMAB + INTERFERON ALPHA-2A VS SUNITINIB IN RENAL CELL CARCINOMA

    Oct 1, 2009, 00:00

  • PIN17 EVALUACI, D.C

    Oct 1, 2009, 00:00

  • PCV109 COST EFFECTIVENESS OF STATIN THERAPY IN SOUTH KOREA

    Oct 1, 2009, 00:00

  • PDB72 QUALITY ADJUSTED LIFE YEARS LOSS DUE TO TYPE 2 DIABETES IN SOUTH KOREA

    Oct 1, 2009, 00:00

  • PHP23 GENERAL PRACTITIONERS PRESCRIPTIONS INDICATORS TRENDS, A TIME-SERIES REVIEW DURING 1998-2003 IN IRAN

    Oct 1, 2009, 00:00

  • PMS10 ECONOMIC BURDEN OF RHEUMATOID ARTHRITIS IN BRAZILIAN PRIVATE HEALTH SYSTEM

    Oct 1, 2009, 00:00

  • PMH53 PATTERNS OF HEALTH CARE RESOURCE UTILIZATION IN JAPANESE PSYCHIATRIC OUTPATIENTS- RESULTS FROM THE ONE-DAY SURVEY CONDUCTED BY THE JAPANESE ASSOCIATION OF NEUROPSYCHIATRIC CLINICS

    Oct 1, 2009, 00:00

  • PMH71 SOCIODEMOGRAPHIC FACTORS AND TOXIC HABITS RELATED TO STUDENT DRUG USE- THE CASE OF THE TECHNOLOGICAL EDUCATIONAL INSTITUTE OF ATHENS

    Oct 1, 2009, 00:00

  • PMH49 COST-EFFECTIVENESS OF QUETIAPINE EXTENDED RELEASE VERSUS OTHER ATYPICAL ANTIPSYCHOTICS IN ACUTE BIPOLAR DEPRESSION

    Oct 1, 2009, 00:00

  • PIN21 CHANGE IN QUALITY OF LIFE AFTER BEING DIAGNOSED WITH HIV

    Oct 1, 2009, 00:00

  • PMS83 COMPARISON OF A GENERIC UTILITY MEASURE (EQ-5D) AND DISEASE SPECIFIC QUALITY OF LIFE INSTRUMENTS IN PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS

    Oct 1, 2009, 00:00

  • PMS8 PREVALENCE OF FIBROMYALGIA IN RUSSIA

    Oct 1, 2009, 00:00

  • PCV81 ECONOMIC IMPLICATIONS OF OBESITY AMONG PEOPLE WITH ATHEROTHROMBOTIC DISEASE IN AUSTRALIA

    Oct 1, 2009, 00:00

  • PND41 IMPROVEMENT IN PATIENT SATISFACTION WITH INCREASING NATALIZUMAB TREATMENT DURATION IN MULTIPLE SCLEROSIS PATIENTS IN THE UNITED STATES

    Oct 1, 2009, 00:00

  • PDB23 PREDICTING COST-EFFECTIVENESS OF A DIABETES HEALTH CARE PROGRAM IN BELGIUM AS A POLICY MANAGEMENT TOOL

    Oct 1, 2009, 00:00

  • PHP14 PROJETO SPIDER- AVALIGICAS NO BRASIL

    Oct 1, 2009, 00:00

  • PUK8 THE COST-EFFECTIVENESS OF PHOSPHATE BINDERS FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN CHRONIC KIDNEY DISEASE (CKD)

    Oct 1, 2009, 00:00

  • PMC26 LINKING PERSON-LEVEL INPATIENT DATA TO LONGITUDINAL RECORDS

    Oct 1, 2009, 00:00

  • PMH16 PREDICTIVE FACTORS FOR HOSPITALIZATION IN FRENCH SCHIZOPHRENIC PATIENTS

    Oct 1, 2009, 00:00

  • PSY59 REVIEW OF RECOMMENDATIONS OF HEALTH TECHNOLOGY ASSESSMENTS ON ORLISTAT AND SIBUTRAMINE

    Oct 1, 2009, 00:00

  • MO11 WHEN DOES VALUE OF INFORMATION ANALYSIS ADD VALUE?

    Oct 1, 2009, 00:00

  • PND4 COST-EFFECTIVENESS ANALYSIS OF INTRAVENOUS IMMUNOGLOBULIN AND PLASMA EXCHANGE THERAPIES FOR THE TREATMENT OF GUILLAIN-BARR SYNDROME IN A UNIVERSITY-BASED HOSPITAL IN THE SOUTH OF BRAZIL

    Oct 1, 2009, 00:00

  • PHP80 CLINICAL EFFECTIVENESS OF PORTABLE ULTRASOUND IN SMALL EMERGENCY DEPARTMENTS- A SYSTEMATIC REVIEW

    Oct 1, 2009, 00:00

  • PHP89 ARE INCREMENTAL BENEFITS FROM MEDICAL CARE DECREASING? AN ANALYSIS OF QALY GAINS OVER TIME

    Oct 1, 2009, 00:00

  • PDB21 WHO ARE THEY FOOLING?- COST OF DISEASE OR COMPLICATIONS CAN SIGNIFICANTLY BIAS ESTIMATES UNLESS CONTROL (NON-DISEASED) COSTS ARE NOT ALSO ACCOUNTED FOR IN THE ANALYSIS

    Oct 1, 2009, 00:00

  • PCN76 COST-EFFECTIVENESS OF CHEMOPREVENTION WITH DUTASTERIDE BASED ON RESULTS FROM THE REDUCE CLINICAL TRIAL

    Oct 1, 2009, 00:00

  • PDB9 IMPACT OF FDA SAFETY WARNINGS ON SUBSEQUENT DIABETES CARE FOR USERS OF ROSIGLITAZONE

    Oct 1, 2009, 00:00

  • PCV70 MANAGEMENT OF ACUTE ISCHEMIC STROKE (IS) AND ASSOCIATED COSTS OVER A 12-MONTH PERIOD IN FRANCE

    Oct 1, 2009, 00:00

  • PCV36 CONFORMATION OF BLEEDING QUANTITY MEASURED AFTER HEART OPERATIONS UNDER THE EFFECTS OF CERTAIN HARMFUL HABITS AND OPERATIVE DATA

    Oct 1, 2009, 00:00

  • PCN81 COST EFFECTIVENESS ANALYSIS OF BORTEZOMIB IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA PATIENTS IN CANADA

    Oct 1, 2009, 00:00

  • PR4 LINEAR SCORING RULES FOR PATIENT REPORTED OUTCOMES AND PATIENT PREFERENCES

    Oct 1, 2009, 00:00

  • PHP100 PHARMACY STUDY OF NATURAL HEALTH PRODUCT ADVERSE REACTIONS (SONAR)- ACTIVE SURVEILLANCE INCREASES AR REPORTING AND REVEALS TWO NEW INTERACTIONS

    Oct 1, 2009, 00:00

  • PMC45 REVIEWERS CHECKLIST FOR ASSESSING THE QUALITY OF DECISION MODELS

    Oct 1, 2009, 00:00

  • PND22 COST-EFFECTIVENESS OF DONEPEZIL IN ALZHEIMERS DISEASE IN SWEDEN

    Oct 1, 2009, 00:00

  • PSY19 DIRECT AND INDIRECT COSTS FOR PATIENTS WITH OPIOID INDUCED CONSTIPATION (OIC) AFTER TREATMENT WITH STRONG OPIOIDS IN SWEDEN

    Oct 1, 2009, 00:00

  • PMS75 OAKHQOL, A DISEASE-SPECIFIC HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE FOR OSTEOARTHRITIS OF THE LOWER LIMB. VALIDITY AND RESPONSIVENESS

    Oct 1, 2009, 00:00

  • PIN9 MODELO FARMACOECONMICO VORICONAZOL EN ASPERGILOSIS INVASIVA- CASO VENEZUELA

    Oct 1, 2009, 00:00

  • PCN60 TREATMENT COSTS ASSOCIATED WITH METASTATIC BREAST CANCER

    Oct 1, 2009, 00:00

  • PSY1 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF PHARMACOTHERAPIES USED IN CHRONIC LOW BACK PAIN

    Oct 1, 2009, 00:00

  • PCN37 EXPECTED ECONOMIC BURDEN OF TREATING ADVANCED SOFT TISSUE SARCOMAS WITH TRABECTEDIN IN RUSSIA

    Oct 1, 2009, 00:00

  • PIN13 BUDGET IMPACT MODEL- LEVOFLOXACIN VS STANDARD THERAPIES IN THE TREATMENT OF INPATIENT CAP

    Oct 1, 2009, 00:00

  • PSS13 CATARACT SURGERY COST IN PATIENTS WITH AND WITHOUT ASTIGMATISM- A FRENCH NATIONAL DRG DATABASE ANALYSIS

    Oct 1, 2009, 00:00

  • PSY1 FIRST BRAZILIAN REGISTRY OF BIOLOGICAL TREATMENT IN PSORIASIS PATIENTS- PRELIMINARY CONCEPT AND RESULTS

    Oct 1, 2009, 00:00

  • PMC23 UNDERESTIMATION OF UNCERTAINTY IN COST-EFFECTIVENESS ACCEPTABILITY CURVES AND EXPECTED VALUE OF INFORMATION ANALYSES

    Oct 1, 2009, 00:00

  • PDB2 COSTS OF DISEASE COMPLICATIONS RELATED TO DM2 IN MEXICO- A SYSTEMATIC REVIEW

    Oct 1, 2009, 00:00

  • PIN14 BUDGET IMPACT OF HIV POST-EXPOSURE PROPHYLAXIS- AN EXAMPLE OF HOSPITAL POINT OF VIEW AFTER NEW RECOMMENDATIONS IN FRANCE

    Oct 1, 2009, 00:00

  • PIH5 AVALIAO E HISTERECTOMIA

    Oct 1, 2009, 00:00

  • PMS12 USTEKINUMAB RESULTS- IN RAPID, SUSTAINED AND CLINICALLY MEANINGFUL IMPROVEMENTS IN PHYSICAL DISABILITY AND QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS- RESULTS- FROM A RANDOMIZED AND PLACEBO-CONTROLLED PHASE II TRIAL

    Oct 1, 2009, 00:00

  • PSY48 INSOMNIA AMONGST PATIENTS WITH CHRONIC PAIN AND INFLUENCE OF ADJUSTMENT OF PAIN MEDICATION IN GERMANY

    Oct 1, 2009, 00:00

  • PCV6 DEYO-CHARLSON COMORBIDITY INDEX SCORE AND SUBSEQUENT CARDIOVASCULAR DISEASE EVENT RISK AMONG PRIMARY AND SECONDARY RISK DYSLIPIDEMIA MANAGED CARE PATIENTS IN THE UNITED STATES

    Oct 1, 2009, 00:00

  • PMC67 LINGUISTIC ADAPTATION OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) INTO ENGLISH

    Oct 1, 2009, 00:00

  • PCN70 COST EFFECTIVENESS ANALYSIS OF SUNITINIB, BEVACIZUMAB + INTERFERON-ALFA AND TEMSIROLIMUS AS FIRST-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN SWEDEN

    Oct 1, 2009, 00:00

  • PDB9 ECONOMIC EVALUATION OF LONG TERM SOMATOSTATIN ANALOGS IN THE TREATMENT OF ACROMEGALY IN MEXICO- MONOTHERAPY VS SEQUENTIAL THERAPY

    Oct 1, 2009, 00:00

  • PMS36 COST-EFFECTIVENESS OF ZOLEDRONIC ACID ONCE-YEARLY INFUSION IN THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROTIC FRACTURES BASED ON COMPLIANCE AND NUMBER NEEDED TO TREAT APPROACH IN THE TURKISH HEALTH CARE SETTING

    Oct 1, 2009, 00:00

  • PSY57 REIMBURSEMENT OF INNOVATIVE DRUGS IN SLOVAKIA-PHARMACOECONOMICS OF USTEKINUMAB IN PSORIASIS

    Oct 1, 2009, 00:00

  • PIN67 QUALITY OF LIFE AND HEALTH CARE UTILIZATION BURDEN OF HCV-INFECTED PATIENTS IN EUROPE

    Oct 1, 2009, 00:00

  • PHP28 PHARMACEUTICAL CARE IN THE EYES OF THE PATIENT

    Oct 1, 2009, 00:00

  • PCV102 COST-EFFECTIVENESS OF VARIOUS SCENARIOS DIRECTED AT ELEVATED ALBUMINURIA TO PREVENT CARDIOVASCULAR AND RENAL DISEASE IN THE GENERAL POPULATION

    Oct 1, 2009, 00:00

  • PCN20 REAL LIFE TREATMENT DURATION OF SORAFENIB OR SUNITINIB IN FIRST LINE METASTATIC RENAL CELL CARCINOMA PATIENTS- A COMPARATIVE ANALYSIS

    Oct 1, 2009, 00:00

  • PSY33 A COST-UTILITY ANALYSIS OF IDET COMPARED WITH SPINAL FUSION

    Oct 1, 2009, 00:00

  • PDB14 UTILIZACIN Y GASTOS EN SERVICIOS DE SALUD

    Oct 1, 2009, 00:00

  • PMH74 REIMBURSEMENT OF INNOVATIVE DRUGS IN SLOVAKIA- PHARMACOECONOMICS OF AGOMELATIN IN DEPRESSION

    Oct 1, 2009, 00:00

  • PHP92 COMPARISON OF THE TIME TO PREPARE CONTRAST MEDIA INJECTION IN CT SCAN EXAM WITH PREFILLED SYRINGES AND BOTTLES IN 7 EUROPEAN COUNTRIES

    Oct 1, 2009, 00:00

  • PCN129 FACTORS AFFECTING ADMINISTRATION REGIMES AND COSTS ASSOCIATED WITH EIGHT FIRST-LINE CHEMOTHERAPEUTIC DRUGS IN SEVEN COMBINATIONS, IN THE TREATMENT OF MNSCLC

    Oct 1, 2009, 00:00

  • PCV164 PRESSURES FACED BY PEOPLE WHO CARE FOR SOMEBODY DIAGNOSED WITH A CARDIOVASCULAR CONDITION

    Oct 1, 2009, 00:00

  • PMS47 POTENTIAL HEALTH ECONOMIC BENEFITS OF IMPROVING THE CARDIOVASCULAR SAFETY PROFILE OF NSAIDS

    Oct 1, 2009, 00:00

  • PCASE2 REMUNERAO BASEADA EM PERFORMANCE- O QUE EXISTE DE DIFERENTE DA CONSULTA BONIFICADA UTILIZADA EM ALGUMAS UNIMEDS

    Oct 1, 2009, 00:00

  • PMH64 THE POSTTRAUMATIC STRESS AMONG AMBULANCE PERSONNEL IN HUNGARY

    Oct 1, 2009, 00:00

  • CN3 COST-EFFECTIVENESS OF SORAFENIB IN UNRESECTABLE AND/OR METASTATIC RENAL CELL CARCINOMA IN TURKEY

    Oct 1, 2009, 00:00

  • PCN139 FINAL QUALITY OF LIFE (QOL) RESULTS WITH GEOGRAPHICAL ANALYSIS FOR SUNITINIB VERSUS INTERFERON-ALFA, AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)

    Oct 1, 2009, 00:00

  • PIN29 COST OF DIABETIC FOOT INFECTIONS DUE TO MRSA- AN ECONOMIC ANALYSIS OF DATA FROM PATIENTS TREATED WITH LINEZOLID IN SPAIN

    Oct 1, 2009, 00:00

  • PIN74 LEAST COSTLY VACCINATION STRATEGY (WITH OR WITHOUT SCREENING FOR ANTOBODIES) FOR HEPATITIS A, HEPATITIS B, VARICELLA, MEASLES AND TETANUS IN CATALONIA, SPAIN

    Oct 1, 2009, 00:00

  • PHP14 A POLICY ANALYSIS OF THE PORTUGUESE GENERIC MEDICINES MARKET

    Oct 1, 2009, 00:00

  • PCN49 COSTS AND QUALITY OF LIFE OF MULTIPLE MYELOMA (MM) IN ITALY- THE CO.MI.M. STUDY

    Oct 1, 2009, 00:00

  • PSY44 LINGUISTIC VALIDATION OF HAEMOPHILIA-SPECIFIC PATIENT-RATED OUTCOMES (HAEMO-QOL, HAEM-A-QOL, HEMO-SAT) IN UP TO 32 LANGUAGES

    Oct 1, 2009, 00:00

  • DB1 USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING- POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH AND COMPLICATION RISK ESTIMATES

    Oct 1, 2009, 00:00

  • PUK3 FORECASTING SPANISH RENAL REPLACEMENT THERAPY TRENDS FROM REGISTRY DATA- A QUANTILE REGRESSION APPROACH

    Oct 1, 2009, 00:00

  • PCN39 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF USING TEMSIROLIMUS COMPARED TO INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA

    Oct 1, 2009, 00:00

  • PSY21 COST STUDY OF HAEMOPHILIA IN MOROCCO

    Oct 1, 2009, 00:00

  • PHP26 IMPOVERISHING MEDICINES- A CROSS-COUNTRY COMPARISON OF THE AFFORDABILITY OF MEDICINES

    Oct 1, 2009, 00:00

  • MC5 TOWARD AN ECONOMIC FRAMEWORK FOR UNDERSTANDING PERFORMANCE-BASED RISK-SHARING AGREEMENTS FOR INNOVATIVE MEDICAL PRODUCTS

    Oct 1, 2009, 00:00

  • PIN53 COST EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN (RBV) FOR RE-TREATMENT OF HCV GENOTYPE I (Gl) PATIENTS WHO DID NOT RESPOND TO PREVIOUS HCV TREATMENT- A UK PERSPECTIVE

    Oct 1, 2009, 00:00

  • PDB44 EXAMINING THE RELATIONSHIP BETWEEN GLYCEMIC CONTROL AND MEDICATION ADHERENCE IN DIABETIC PATIENTS

    Oct 1, 2009, 00:00

  • PCN92 COST-EFECTIVENESS ANALYSIS OF DOCETAXEL VS DOCETAXEL+TRASTUZUMAB AS FIRST LINE THERAPY IN THE TREATMENT OF PATIENTS WITH METATSTASTIC BREAST CANCER HER2/NEU+

    Oct 1, 2009, 00:00

  • PDB46 UTILITIES FOR INFUSION THERAPY IN TYPE I DIABETES

    Oct 1, 2009, 00:00

  • PCV3 USE OF SPIRONOLACTONE IN THE TREATMENT OF CONGESTIVE HEARTH FAILURE

    Oct 1, 2009, 00:00

  • PG123 STAPLED HAEMORRHOIDOPEXY IN THE TREATMENT OF HAEMORRHOIDAL PROLAPSE-COMPARISON OF HTA REPORTS, FOR TWO ITALIAN REGIONS

    Oct 1, 2009, 00:00

  • PIH22 HEALTH ECONOMIC EVALUATION OF A NEW VACCINE FOR THE PREVENTION OF HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN ADULTS A GERMAN ANALYSIS

    Oct 1, 2009, 00:00

  • PSS16 DECISION MAKING ANALYSIS FOR DIFFERENT NEUROSENSORIAL DEEP HYPOACUSIA TREATMENTS IN COLOMBIA. COSTPRODUCTIVITY ASSESMENT

    Oct 1, 2009, 00:00

  • PIH4 AVALIAO E HISTERECTOMIA

    Oct 1, 2009, 00:00

  • PRS30 IMPACT OF OCULAR SYMPTOMS ON RESOURCE UTILISATION AND WORK PRODUCTIVITY IN MANAGEMENT OF AR-AN OBSERVATIONAL, CROSS SECTIONAL STUDY IN 4 COUNTRIES IN EUROPE

    Oct 1, 2009, 00:00

  • PCV167 A CLUSTER RANDOMIZED CONTROLLED TRIAL TO EVALUATE AN AMBULATORY PRIMARY CARE MANAGEMENT PROGRAM FOR PATIENTS WITH DYSLIPIDEMIA- TEAM STUDY

    Oct 1, 2009, 00:00

  • PSY25 RENAL ANEMIA (RA) TREATMENT IN MEXICAN PUBLIC HEALTH CARE INSTITUTIONS- AN EVALUATION OF THE COSTS AND CONSEQUENCES

    Oct 1, 2009, 00:00

  • PCN22 COMPARING THE SURVIVAL BENEFIT OF LETROZOLE AND ANASTROZOLE- A NUMBER NEEDED TO TREAT ANALYSIS

    Oct 1, 2009, 00:00

  • PG110 ECONOMIC EVALUATION OF A MULTIDISCIPLINARY SUPPORT PROGRAM IN HEPATITIS C TREATMENT- PRELIMINARY RESULTS

    Oct 1, 2009, 00:00

  • PCN123 LONG-TERM COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN-AN UPDATED ANALYSIS BASED UPON THE 100 MONTH FOLLOW UP OF THE ANASTROZOLE OR TAMOXIFEN ALONE OR IN COMBINATION (ATAC) TRIAL

    Oct 1, 2009, 00:00

  • PCN18 OUTCOMES RESEARCH OF BORTEZOMIB INDICATED FOR MULTIPLE MYELOMA IN THE CONTEXT OF THE DUTCH REIMBURSEMENT POLICY FOR EXPENSIVE MEDICINES- THREATS TO THE INTERNAL VALIDITY OF THE INCREMENTAL EFFECTIVENESS ESTIMATE

    Oct 1, 2009, 00:00

  • PMC75 ARE ONLINE MANAGED PHYSICIAN PANELS A VIABLE SOURCE FOR SCIENTIFIC RESEARCH INITIATIVES?

    Oct 1, 2009, 00:00

  • PMH42 COST-EFFECTIVENESS ANALYSIS OF OLANZAPINE LONG-ACTING INJECTION COMPARED WITH RISPERIDONE LONG-ACTING INJECTION IN THE TREATMENT OF SCHIZOPHRENIA IN NORWAY

    Oct 1, 2009, 00:00

  • PSY2 EFFECT OF WRITTEN EMOTIONAL DISCLOSURE INTERVENTIONS IN PERSONS WITH PSORIASIS UNDERGOING NARROW BAND ULTRAVIOLET B PHOTOTHERAPY

    Oct 1, 2009, 00:00

  • PMC61 CATALOGUE OF EQ-5D SCORES FOR THE UK

    Oct 1, 2009, 00:00

  • PG117 CONSUMPTION OF HEALTH CARE RESOURCES ASSOCIATED WITH CURRENT MANAGEMENT STRATEGIES FOR NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING- AN OBSERVATIONAL EUROPEAN STUDY

    Oct 1, 2009, 00:00

  • PSS42 INTERVENTIONAL PROCEDURES IN GLAUCOMA- RESOURCES AND COSTS IN FIVE EUROPEAN COUNTRIES

    Oct 1, 2009, 00:00

  • CO4 MICRO-COSTING VS GROSS-COSTING IN THE ESTIMATION OF COSTS FOR THE PHARMACOECONOMIC EVALUATION OF GLAUCOMA IN KOREA

    Oct 1, 2009, 00:00

  • PG111 THE COST EFFECTIVENESS OF INFLIXIMAB IN THE TREATMENT OF ACUTE ULCERATIVE COLITIS PATIENTS IN SCOTLAND

    Oct 1, 2009, 00:00

  • PMC20 IMPLEMENTING A BENCHMARKING MODEL FOR EXPENDITURES OF PRESCRIPTION DRUGS IN AUSTRIA

    Oct 1, 2009, 00:00
  • «
  • 141
  • 142 (current)
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • »